MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03501nam a22005057a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220124s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1098-3600 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1038/s41436-021-01269-9 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1038/s41436-021-01269-9 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
NIHMS1734682 [mid] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC8633054 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
34282303 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. |
| 251 ## - Source |
|---|
| Source |
Genetics in Medicine. 23(12):2335-2341, 2021 12. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Genet Med. 23(12):2335-2341, 2021 12. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Genet Med. 23(12):2335-2341, 2021 Dec. |
| 253 ## - Journal Name |
|---|
| Journal name |
Genetics in medicine : official journal of the American College of Medical Genetics |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2021 Dec |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-07-26 |
| 268 ## - Previous citation |
|---|
| -- |
Genetics in Medicine. 23(12):2335-2341, 2021 Dec. |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 2002 - 2011 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSION: These findings should inform the establishment of future implementation efforts at institutions considering a pre-emptive PGx testing program. Copyright (c) 2021. The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: In this report, we compare and contrast implementation strategies for pre-emptive PGx testing by 15 early-adopter institutions. We surveyed these groups, collecting data on testing approaches, team composition, and workflow dynamics, in addition to estimated third-party reimbursement rates. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
PURPOSE: The increased availability of clinical pharmacogenetic (PGx) guidelines and decreasing costs for genetic testing have slowly led to increased utilization of PGx testing in clinical practice. Pre-emptive PGx testing, where testing is performed in advance of drug prescribing, is one means to ensure results are available at the time of prescribing decisions. However, the most efficient and effective methods to clinically implement this strategy remain unclear. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: We found that while pre-emptive PGx testing models varied across sites, institutions shared several commonalities, including methods to identify patients eligible for testing, involvement of a precision medicine clinical team in program leadership, and the implementation of pharmacogenes with Clinical Pharmacogenetics Implementation Consortium guidelines available. Finally, while reimbursement rate data were difficult to obtain, the data available suggested that reimbursement rates for pre-emptive PGx testing remain low. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Pharmacogenetics |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Pharmacogenomic Testing |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Drug Prescriptions |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Genetic Testing |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacogenetics/mt [Methods] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Precision Medicine/mt [Methods] |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Health |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Pharmacogenomics |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Smith, D Max |
| 790 ## - Authors |
|---|
| All authors |
Aquilante CL, Beitelshees AL, Cavallari LH, Cicali EJ, Dalton R, Duarte JD, Duong BQ, Elchynski AL, Empey PE, Hicks JK, IGNITE Network Pharmacogenetics Working Group, Johnson JA, Lee JC, Obeng AO, Pasternak AL, Petry NJ, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Van Driest SL, Wiisanen K |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1038/s41436-021-01269-9">https://dx.doi.org/10.1038/s41436-021-01269-9</a> |
| Public note |
https://dx.doi.org/10.1038/s41436-021-01269-9 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
